# Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

> **NCT01491932** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 129 (actual)

## Conditions studied

- Dyskinesias
- Parkinson Disease
- Movement Disorders
- Parkinsonian Disorders
- Anti-Dyskinesia Agents

## Interventions

- **DRUG:** AFQ056

## Key facts

- **NCT ID:** NCT01491932
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2020-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491932, "Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01491932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*